Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
FDA Approvals
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Read More
FDA Approvals
,
Prostate Cancer
,
Select Drug Profiles
Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Read More
FDA Approvals
,
Select Drug Profiles
Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping
Read More
FDA Approvals
,
Select Drug Profiles
Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations
Read More
FDA Approvals
,
Select Drug Profiles
FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications
Read More
FDA Approvals
,
Select Drug Profiles
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Read More
FDA Approvals
,
Select Drug Profiles
FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma
Read More
FDA Approvals
,
Urothelial Cancer
,
Select Drug Profiles
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
Read More
12
13
14
15
16
17
18
Page 15 of 31
Results 141 - 150 of 305